ULCERATIVE COLITIS (UC)

This study tests a sequential treatment for moderate to severe ulcerative colitis. Patients first receive a fast-acting drug (upadacitinib) for 8 weeks, then switch to a safer long-term drug (vedolizumab) for maintenance. The goal is to quickly induce remission while reducing sid…

This study tests whether taking vitamin D3 supplements can lower inflammation in people with moderate ulcerative colitis. Sixty adults aged 20-40 will either get standard care plus a placebo or standard care plus a high dose of vitamin D3 every two weeks for 12 weeks. Researchers…

This study looks at people with ulcerative colitis whose disease is still active after trying at least two advanced medications. Participants choose either to continue trying different drugs or to have surgery to remove the colon. The study will compare quality of life, daily fun…

This Canadian study is testing whether switching to the drug guselkumab (Tremfya) can help people with inflammatory bowel disease (IBD) who didn't get enough relief from ustekinumab. Researchers will track symptoms and test results for 200 participants over one year. The goal is …

This study is testing whether a smartphone app called SMART-IBD can help teenagers with inflammatory bowel disease (IBD) remember to take their medications and manage their symptoms. About 70 teens aged 13-17 will either use the full app with reminders and challenges or just a si…

This study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control sympt…

This study tests several new investigational drugs in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The goal is to see if these treatments are safe and can reduce gut inflammation, improve symptoms, and help the bowel heal. Participants will receive on…

This study is testing whether adding the allergy drug desloratadine to standard treatment (mesalamine) can reduce inflammation and improve symptoms in people with mild to moderate ulcerative colitis. About 44 adults aged 18 to 65 with active disease are being recruited. The goal …

This study looks at whether people with ulcerative colitis (UC) who are in deep remission (no signs of inflammation) can safely reduce or stop their medication. Researchers will compare two groups: those who continue their current therapy and those who decrease or stop it. The go…

This study looks at whether teaching children and teens with inflammatory bowel disease (IBD) about ultra-processed foods (like packaged snacks and sugary drinks) can help them eat less of them. About 120 participants will complete online food diaries and receive either nutrition…

This study is a large registry that will follow 10,000 people with inflammatory bowel disease (IBD) in Germany over many years. Its goal is to collect real-world information on how well treatments work, how the disease changes over time, and how it affects patients' daily lives. …